688289 Stock Overview
Engages in the research and development, production, and sale of in vitro diagnostic reagents and instruments in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Sansure Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥22.45 |
| 52 Week High | CN¥25.58 |
| 52 Week Low | CN¥16.08 |
| Beta | 0.70 |
| 11 Month Change | 1.17% |
| 3 Month Change | 22.81% |
| 1 Year Change | 23.56% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -39.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688289 | CN Medical Equipment | CN Market | |
|---|---|---|---|
| 7D | -0.3% | -0.4% | -0.9% |
| 1Y | 23.6% | -7.3% | 5.4% |
Return vs Industry: 688289 exceeded the CN Medical Equipment industry which returned -7.3% over the past year.
Return vs Market: 688289 exceeded the CN Market which returned 5.4% over the past year.
Price Volatility
| 688289 volatility | |
|---|---|
| 688289 Average Weekly Movement | 8.9% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 688289 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688289's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 2,209 | Lizhong Dai | www.sansure.com.cn |
Sansure Biotech Inc. engages in the research and development, production, and sale of in vitro diagnostic reagents and instruments in China. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tract infections; nucleic acid tests and fluorescence diagnostic kits for blood-borne infections; RNA diagnostic kits for gastrointestinal infections; and diagnostic kits for monkeypox, epstein-barr virus, and human cytomegalovirus DNA, as well as rapid antigen tests. The company provides nucleic acid extraction or purification kits, multi-type sample DNA/RNA extraction-purification kits, and sample release reagents; sample storage reagents for SARS-CoV-2; extraction instruments and systems; and PCR instruments comprising real-time quantitative thermal cyclers, portable molecule workstations, and real-time PCR systems.
Sansure Biotech Inc. Fundamentals Summary
| 688289 fundamental statistics | |
|---|---|
| Market cap | CN¥12.86b |
| Earnings (TTM) | CN¥259.42m |
| Revenue (TTM) | CN¥1.41b |
49.6x
P/E Ratio9.1x
P/S RatioIs 688289 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688289 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.41b |
| Cost of Revenue | CN¥315.49m |
| Gross Profit | CN¥1.09b |
| Other Expenses | CN¥832.24m |
| Earnings | CN¥259.42m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.45 |
| Gross Margin | 77.58% |
| Net Profit Margin | 18.44% |
| Debt/Equity Ratio | 5.6% |
How did 688289 perform over the long term?
See historical performance and comparison